One of the main causes of hospital-acquired infections (HAIs) is the colonization of bacteria around catheter entry sites. If not removed, these bacteria can form biofilms and enter the bloodstream, causing bloodstream infections (BSIs) that account for about 7.3% of all HAIs. Hence, there is a strong need for an efficient technology capable or preventing BSIs due to intravenous catheters. The patented Aseptuva far-UVC technology is designed to reduce this BSIs by disinfecting the skin safely and effectively at the catheter entry site using deep UV light. Indeed, light at 213 nm has the ability to removes bacterial films without damaging the exposed skin. Nonetheless, pervious studies showed that the interaction between UVC light and human skin is a complex process triggering various biological and chemical reactions. UVC does not directly heat the skin but can cause secondary inflammation, visible as redness (erythema) and / or mild temperature rise. However, similar signs can also result from fever or environmental factors, making it difficult to identify the cause. To minimize potential inflammation and monitor the antimicrobial effect of the technology, Aseptuva is developing together with ZHAW a smart monitoring system. The first step includes integrating directly in the catheter a non-contact thermal sensor that detects small temperature changes (±0.2 °C accuracy). Such a sensor will allow to adjust the UVC dose and will make next generation device safer to use and more efficient.
Kabir et al. (Mon,) studied this question.